Formosa Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Taiwanfocusing On Developing Drug Candidates In Ophthalmologyoncologyand Anti Infectivesthe Company Is Listed On The Taiwan Stock Exchange Under The Ticker Tpe 6838 Formosa Leverages Its Proprietary Active Pharmaceutical Nanoparticle Technologyapnta To Create Innovative Drug Delivery Systemsparticularly For Ophthalmic Applicationstheir Lead Productapp13007Is A Us Fda Approved Ophthalmic Nanosuspension Designed To Provide Rapid Anti Inflammatory And Pain Relief After Cataract Surgeryin Oncologyformosa Is Developing Tsy 0110A Biosimilar For Her2 Positive Breast Canceras Part Of Its Focus On Antibody Drug Conjugate Biosimilars And Small Molecule New Chemical Entitiesthe Company Also Explores The Use Of Its Apntatechnology In Anti Infective Drug Development Formosa Pharmaceuticals Actively Collaborates With Global Partners To Enhance Its Pipeline And Expand Its Capabilities In The Biopharmaceutical Sector
